Cravatt Benjamin 4
4 · ALNYLAM PHARMACEUTICALS, INC. · Filed Jun 3, 2026
Research Summary
AI-generated summary of this filing
Alnylam Director Benjamin Cravatt Receives Award of 4,393 Shares
What Happened
Benjamin Cravatt, a director of Alnylam Pharmaceuticals (ALNY), was granted a derivative award covering 4,393 shares on June 1, 2026. The Form 4 reports an acquisition price of $0.00 and classifies the transaction as an award/grant (derivative). This is a compensation-related option award rather than an open-market purchase or sale.
Key Details
- Transaction date: 2026-06-01; filing date: 2026-06-03.
- Transaction type: Award/Grant of a derivative (stock option) — 4,393 shares; reported acquisition price $0.00.
- Vesting: The award vests one-third on each of the first, second and third anniversaries of the grant date (per footnote).
- Shares owned after transaction: Not specified in the provided filing.
- Timeliness: Filed within a typical Form 4 window (no late filing flag indicated).
Context
This was a standard equity compensation grant to a director. As a derivative (stock option) award, it does not represent an immediate cash purchase or sale; value will depend on future stock performance and the option’s exercise terms. Such grants are common for director compensation and do not by themselves signal a personal buy or sell decision.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-06-01+4,393→ 4,393 totalExercise: $295.63From: 2027-06-01Exp: 2036-06-01→ Common Stock (4,393 underlying)
Footnotes (1)
- [F1]The stock option will vest as to one third of the shares on each of the first, second and third anniversaries of the date of grant.